Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
The deal between the White House and Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Danger is lurking in the stock market: An abrupt sell-off could be around the corner if the Federal Reserve doesn't deliver the rate cut the market expects next week, the firm...Marketsread more
At Rockets of Awesome, Scott Turner will be a senior vice president responsible for digital and marketing. He'll report to founder Rachel Blumenthal, wife to Warby Parker...Retailread more
Shares of Beyond Meat jumped 12% Monday afternoon, nearing its all-time high, on investor optimism ahead of its earnings.Food & Beverageread more
"Even a 50-basis point reduction would still keep the Fed funds rate well above zero," Shelton told The Washington Post in an email.The Fedread more
The stocks of several utilities opened lower, after weekend power outages during a major heat wave and from severe storms.Market Insiderread more
Also in Epstein's address book is supermarket mogul Ron Burkle, Chelsea Clinton, former Secretaries of State Henry Kissinger and John Kerry, and media titan Rupert Murdoch,...Politicsread more
(Deletes paragraph 9 to clarify that retreatment with Polivy has not been studied)
June 10 (Reuters) - The U.S. Food and Drug Administration on Monday granted earlier-than-expected approval to Roche Holding
AG's antibody- Polivy for treatment of patients
with advanced lymphoma.
Polivy was approved in combination with Roche's older drug Rituxan and a chemotherapy agent for adult patients with advanced diffuse large B-cell lymphoma (DLBCL) whose cancer has worsened despite at least two previous lines of therapy.
Antibody-drug conjugates are designed to deliver a toxic chemotherapy directly to tumors.
Roche said the average U.S. list price for a four-month course of Polivy would be $90,000. Rituxan is priced at $39,500 for four months.
Wall Street analysts estimate Polivy sales at nearly $1 billion by 2024, according to IBES data from Refinitiv.
Side effects seen in studies of Polivy included low blood cell counts, nerve damage, fatigue and pneumonia, the FDA said in a statement.
Cell therapies Yescarta, from Gilead Sciences Inc and Kymriah, sold by Novartis AG, are also approved for patients with advanced DLBCL.
Dr. Matthew Matasar, a hematologist at New York's Memorial Sloan Kettering Cancer Center who was involved in the development of Polivy, said the drug could be an option for some patients to try before determining whether they need to move on to CAR-T treatments.
Roche estimates that nearly 25,000 new cases of DLBCL, a type of non-Hodgkin's lymphoma (NHL), will be diagnosed in the United States this year.
NHL, which is one of the most common cancers, accounts for about 4% of all types of cancers in the United States, according to the American Cancer Society.
Continued approval for the treatment may depend on data from a confirmatory trial, Roche said.
The FDA's accelerated approval program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. (Reporting by Aakash Jagadeesh Babu in Bengaluru and Deena Beasley in Los Angeles; Editing by James Emmanuel and Lisa Shumaker )